recently reported on CENTOGENE’s expanding relationship with Lifera, a biopharma company owned by the PIF. This news comes as CENTOGENE N.V. recorded a cumulative net loss of $-36 million during the 12 months ending in the fourth quarter of 2022.
Despite facing challenges in the Medical Laboratories industry, with employees of 14 other companies reaching higher income per employee, CENTOGENE N.V.’s overall ranking has deteriorated compared to the third quarter of 2022, dropping from 0 to 2629.
In response to these financial pressures, CENTOGENE has secured approximately $20 million to strengthen its cash position. This strategic move not only bolsters the company’s financial stability but also paves the way for further growth and collaboration with Lifera.
The partnership between CENTOGENE and Lifera demonstrates a commitment to innovation and advancement in the biopharma industry. With this influx of funds, CENTOGENE is well-positioned to navigate market challenges and drive future success.
Comments